Where does Intellia Therapeutics's cash flow data come from?

Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q2 '26	Q1 '26	Q4 '25	Q3 '25	Q2 '25
Net income	——	-$96.23M+15.8%	-$95.79M+25.7%	-$101.32M+25.3%	-$101.26M+31.1%
Depreciation and amortization	——	$2.2M-11.8%	$2.38M-7.2%	$2.4M-7.7%	$2.5M-3.8%
Stock-based compensation	——	$13.48M-38.3%	$16.74M-57.7%	$19.6M-50.5%	$22.04M-46.1%
Change in accounts receivable	——	-$337K-117%	——	——	$849K+104%
Change in accounts payable	——	-$1.42M+24.0%	$6.96M+385%	$3.46M—	-$2.56M-148%
Change in accrued liabilities	——	-$11.95M+17.1%	——	-$715K—	——
Change in other assets	——	$12.97M+6,050%	$8.69M+1,706%	$23.04M+312%	-$5.16M-106%
Change in deferred revenue	——	-$6.66M-30.7%	-$13.98M-139%	-$4.91M+10.4%	-$4.13M+23.4%
Net gains (losses) on investments	——	-$904K+57.5%	-$2.65M+13.9%	$3.44M+212%	$1.34M+107%
Net cash from operating activities	——	-$117.35M+21.2%	-$69.29M+18.7%	-$76.9M+9.4%	-$99.62M-71.2%
Capital expenditures	——	$79K-89.3%	$126K-87.2%	$29K-97.7%	$239K-76.4%
Net cash from investing activities	——	$66.31M-29.7%	$27.53M-81.8%	$0+100%	$106.91M+542%
Proceeds from issuance of common stock	$194.6M—	——	$128.08M-25.6%	$97K-94.3%	$0-100%
Net cash from financing activities	——	$33.57M—	$1.98M-14.7%	$114.86M+39.7%	$14.65M-64.5%
Net increase (decrease) in cash	——	-$17.47M+68.0%	-$39.77M—	$37.22M+459%	——
Accretion (Amortization) of Discounts and Premiums, Investments	——	$535K-76.5%	$826K-77.1%	$1.09M-74.7%	$1.67M-64.1%
Gain (Loss) on Investments	——	-$904K+57.5%	-$2.65M+13.9%	$3.44M+212%	$1.34M+107%
Increase Decrease In Operating Lease Liabilities	——	-$12.84M+55.8%	-$4.64M-9.2%	-$4.63M+1.0%	-$16.66M-265%
Increase Decrease In Operating Right Of Use Assets	——	-$8.41M-16.5%	-$8.29M-29.1%	-$8.64M-70.1%	-$8.93M-78.2%
Increase (Decrease) in Other Operating Assets	——	$74K-99.5%	-$1.94M—	-$25.29M—	$10.59M+1,477%
Increase (Decrease) in Prepaid Expense and Other Assets	——	$12.97M+6,050%	$8.69M+1,706%	$23.04M+312%	-$5.16M-106%
Accrued payables for capital expenditures	——	$0-100%	$32K-84.2%	$0—	-$82K—
Leased assets obtained in exchange for operating lease liabilities	——	——	$0-100%	$0-100%	$0-100%
Reduction Of Right Of Use Assets From Remeasurement Of Lease Liabilities	——	$0-100%	——	——	——
Free cash flow	——	-$117.43M+21.5%	-$69.41M+19.5%	-$76.93M+10.7%	-$99.86M-68.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Intellia Therapeutics's cash flow data come from?: Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.